[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100628681":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":24,"centralContacts":29,"locations":35,"responsibleParty":52,"collaborators":24,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":24,"eligibilityCriteria":59,"healthyVolunteers":56,"sex":60,"minAge":61,"maxAge":24,"enrollmentInfo":62,"targetDuration":24,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":24,"overallStatus":37,"whyStopped":24,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"Ain Shams University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"control (weight based) group","ACTIVE_COMPARATOR","Group 1 (weight-based):\n\n* Enoxaparin (subcutaneously) adjusted for weight: 1mg\u002Fkg twice daily.\n* For obese and morbidly obese patients, 1 mg\u002Fkg Q 12 h dose will be given up to weights of approximately 150 kg. The maximum dose of enoxaparin should be 150 mg SC Q 12 h.\n* Patients weighing \\\u003C 45 kg were not included in clinical trials; therefore, these patients should also be monitored using the low molecular weight heparin assay.\n* No routine anti-Xa monitoring unless clinically indicated. follow up of venous thrombo embolic events.",[13],"Other: follow up venous thromboembolic events with no routine clexan dosage modification and no usage of anti factor 10 assay",{"label":15,"type":10,"description":16,"interventionNames":17},"active antifactor xa based group","Group 2 (anti-Xa-based):\n\n* Initial dose as standard: 1mg\u002Fkg twice daily; peak anti-Xa level measured 4 hours after third dose, Target: 0.2-0.4 IU\u002Fml for prophylaxis\n* Adjustments: Increase by 10 mg if \\\u003C0.2 IU\u002FmL; decrease by 10 mg if \\>0.4 IU\u002Fml\n* Re-check after 3 modified doses until the target level is achieved.\n* Prophylaxis continues until mobilization or discharge follow up of venous thrombo embolic events.",[18],"Other: follow up venous thrombo embolic events with routine clexan dose modification guided by anti factor 10 assay",[20,25],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"follow up venous thrombo embolic events with routine clexan dose modification guided by anti factor 10 assay","follow up vte incidence and routine clexan dose modification",[15],null,{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"follow up venous thromboembolic events with no routine clexan dosage modification and no usage of anti factor 10 assay","follow up of vte incidence with no routine dose modification unless indicated",[9],[30],{"name":31,"role":32,"phone":33,"phoneExt":24,"email":34},"Doaa Ahmed Diaa El din Ibrahim, MD","CONTACT","01128904628","Doaaeldin@med.asu.edu.eg",[36],{"facility":5,"status":37,"city":38,"state":39,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"RECRUITING","Cairo","Abbassia","00202","Egypt","EG",{"type":44,"coordinates":45},"Point",[46,47],31.24967,30.06263,{"lat":47,"lon":46},[50],{"name":51,"role":32,"phone":33,"phoneExt":24,"email":34},"Doaa Ahmed Diaa Eldin Ibrahim, MD",{"type":53,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100628681","utilizing-anti-factor-xa-as-a-predictive-tool-for-optimizing-outcome-in-burn-patients-management-100628681",false,"NCT07464808","Utilizing Anti-Factor Xa as a Predictive Tool for Optimizing Outcome in Burn Patients' Management","Inclusion Criteria:\n\n1. Adults (≥21 years) admitted to the burn unit with thermal burns ≥20% TBSA and \\\u003C 60%.\n2. Admission to BICU within 48 hours of burn injury.\n3. Indication for VTE prophylaxis (e.g., immobilized, surgical intervention).\n4. Ability to provide informed consent\n\nExclusion Criteria:\n\n1. Pre-existing coagulopathy or anticoagulant therapy prior to injury.\n2. Patients with severe comorbidities (e.g., end-stage renal failure, advanced malignancy, hepatic disease).\n3. Need for therapeutic anticoagulant therapy.\n4. patients with extremes of weight, (45kg \\>=weight \\>= 150kg).","ALL","21 Years",{"count":63,"type":64},25,"ESTIMATED","INTERVENTIONAL",[67],"NA","This study aims to compare the efficacy of anti-Xa based versus weight-based enoxaparin dosing and to evaluate anti-Xa levels as a predictive tool for clinical outcomes in burn patients",[70],"Venous Thromboembolic Event","2026-03-09",{"date":73,"type":74},"2026-03-11","ACTUAL",{"date":76,"type":74},"2025-11-28",{"date":78,"type":64},"2027-11-30",{"name":5,"class":6},1]